Zurich Cantonal Bank
CERE

Zurich Cantonal Bank’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Zurich Cantonal Bank’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,170
Closed -$539K – 2686
2024
Q2 		$539K Hold
13,170
– – ﹤0.01% 1439
2024
Q1 		$557K Hold
13,170
– – ﹤0.01% 1395
2023
Q4 		$558K Buy
13,170
+1,091
+9% +$31.3K ﹤0.01% 1427
2023
Q3 		$264K Buy
12,079
+1,925
+19% +$48.2K ﹤0.01% 1799
2023
Q2 		$323K Hold
10,154
– – ﹤0.01% 1635
2023
Q1 		$248K Hold
10,154
– – ﹤0.01% 1739
2022
Q4 		$320K Buy
10,154
+3,020
+42% +$85.2K ﹤0.01% 1529
2022
Q3 		$202K Hold
7,134
– – ﹤0.01% 1751
2022
Q2 		$189K Hold
7,134
– – ﹤0.01% 1823
2022
Q1 		$250K Buy
7,134
+1,657
+30% +$48.4K ﹤0.01% 1754
2021
Q4 		$178K Buy
5,477
+2,478
+83% +$87.4K ﹤0.01% 2149
2021
Q3 		$88K Buy
+2,999
New +$84.2K ﹤0.01% 2407

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Zurich Cantonal Bank's CERE Position: Q3 2024 in Review

Zurich Cantonal Bank sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 13,170 shares — an estimated $539K sold.

Zurich Cantonal Bank first reported a position in CERE in Q3 2021 and held it in 12 quarters. The position peaked at $558K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Zurich Cantonal Bank reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Zurich Cantonal Bank sold 13,170 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $539K.
  • Zurich Cantonal Bank first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Zurich Cantonal Bank's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $558K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Zurich Cantonal Bank's 13F filing for Q3 2024, filed 8 Nov 2024.